Phreesia, INC Form 4 insider transactions

Michael Weintraub, a director of Phreesia Inc., filed an amended Form 4 to correct an overstatement of direct share ownership in a previous filing.

Balaji Gandhi, CFO of Phreesia, Inc., sold 1,827 shares of common stock on March 26, 2025, to cover tax withholding obligations related to the settlement of restricted stock units.

David Linetsky, SVP of Life Sciences at Phreesia, Inc., reported the sale of common stock to cover tax withholding obligations related to the settlement of restricted stock units.

Allison C. Hoffman, General Counsel & Secretary of Phreesia, Inc., sold 3,496 shares of common stock at $25.32 per share on March 17, 2025, under a pre-arranged trading plan.

Evan Roberts, Chief Operating Officer of Phreesia, Inc., sold shares of common stock on February 18 and 19, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Balaji Gandhi, CFO of Phreesia, Inc., sold shares of common stock on February 18 and 19, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Allison Hoffman, General Counsel & Secretary of Phreesia Inc., sold 3,496 shares of common stock at $29.72 per share on February 18, 2025, under a pre-arranged 10b5-1 trading plan.

Phreesia's Chief Operating Officer, Evan Roberts, executed sales of common stock on February 13 and 14, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Balaji Gandhi, CFO of Phreesia, Inc., sold a portion of his common stock holdings on February 13 and 14, 2025, under a pre-arranged Rule 10b5-1 trading plan.

David Linetsky, SVP of Life Sciences at Phreesia, Inc., sold 11,616 shares of common stock at an average price of $29.7005 per share under a pre-arranged 10b5-1 trading plan.

David Linetsky, SVP of Life Sciences at Phreesia, Inc., sold 300 shares of common stock at an average price of $29.5233 under a pre-arranged 10b5-1 trading plan.

David Linetsky, SVP of Life Sciences at Phreesia, Inc., sold 720 shares of common stock at an average price of $29.5013 per share on February 5, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Director Gillian Munson acquired 351 shares of Phreesia Inc. common stock at $28.46 per share on January 31, 2025, through deferred stock units.

A Phreesia director has elected to receive deferred stock units instead of a cash retainer, according to a recent SEC filing.

Director Edward Cahill acquired 351 shares of Phreesia, Inc. common stock through deferred stock units, increasing his total holdings to 47,383 shares.

David Linetsky, SVP of Life Sciences at Phreesia, sold 500 shares of common stock at an average price of $29.682, as part of a pre-arranged trading plan.

Balaji Gandhi, CFO of Phreesia, Inc., sold shares of common stock on January 27, 2025, to cover tax withholding obligations related to the settlement of performance-based restricted stock units.

Allison Hoffman, General Counsel & Secretary of Phreesia Inc., sold shares of common stock on January 27 and 28, 2025, to cover tax withholding obligations and pursuant to a pre-arranged trading plan.

David Linetsky, SVP of Life Sciences at Phreesia, Inc., sold shares of common stock to cover tax withholding obligations related to the settlement of performance-based restricted stock units.

Phreesia Inc.'s Chief Operating Officer, Evan Roberts, disposed of shares to cover tax withholding obligations related to the settlement of performance-based restricted stock units.

Phreesia's CEO, Chaim Indig, disposed of shares to cover tax withholding obligations related to the settlement of performance-based restricted stock units.

Amy Beth VanDuyn, SVP of Human Resources at Phreesia Inc., sold shares of common stock to cover tax withholding obligations related to the settlement of performance-based restricted stock units.

Phreesia Inc.'s Principal Accounting Officer, Yvonne Hui, sold 127 shares of common stock at $28 per share on January 24, 2025, under a pre-arranged 10b5-1 trading plan.

Phreesia's Chief Financial Officer, Balaji Gandhi, acquired 7,900 shares of common stock due to the vesting of performance-based restricted stock units.

Allison Hoffman, General Counsel & Secretary at Phreesia Inc., acquired 12,791 shares of common stock due to the vesting of performance-based restricted stock units.

Phreesia's CEO, Chaim Indig, acquired 48,910 shares of common stock due to the vesting of performance-based restricted stock units.

David Linetsky, SVP of Life Sciences at Phreesia, acquired 19,564 shares of common stock due to the vesting of performance-based restricted stock units.

Phreesia Inc.'s Chief Operating Officer, Evan Roberts, acquired 19,564 shares of common stock due to the vesting of performance-based restricted stock units.

Amy Beth VanDuyn, SVP of Human Resources at Phreesia, Inc., acquired 7,900 shares of common stock due to the vesting of performance-based restricted stock units.

Phreesia's Chief Financial Officer, Balaji Gandhi, sold 5,827 shares of common stock to cover tax obligations related to the settlement of restricted stock units.